Compare Cronos Group Inc (CRON) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Tapestry, Inc. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Tapestry, Inc. trades at $116.26 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 19.6× Cronos Group Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Tapestry, Inc. for 70 Days on average.
| CRON | TPR | |
|---|---|---|
Market Cap | $1.18B | $23.09B |
Volume | 968,037 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $3.55 | $164.78 |
52-Week Low | $2.30 | $98.81 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $387.62M | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
TPR trades at $116.26, up 2.53% today, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a high ROE of 197.14% highlight operational strength, though net income margin fell sharply in 2025. The stock is supported by a $174.64 consensus price target and positive news on international growth, but faces risks from tariffs and Kate Spade execution challenges.
Outlook remains positive with 73% buy ratings and projected revenue growth to $8.0B in 2026. Key opportunities include margin expansion and Coach brand momentum, while risks involve volatile cash flows, high debt, and competitive pressures. The current price offers a 50% upside to the consensus target, but investors should monitor earnings delivery and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
